Abstract Details

Title Hand Preference and Learning Disability Differentially Distribute across PPA Variants

Topic Aging and Dementia

Presentation(s) P03 - (-)

Poster/Presentation
Number 093

Objective

Background BACKGROUND: Primary Progressive Aphasia consists of 3 variants - logopenic, nonfluent, and semantic. Each subtype correlates with distinct anatomical involvement and typically with discrete underlying pathology. Prior literature on the development of PPA suggests a correlation with neurodevelopment as evidenced by increased rate of learning disability among patients with PPA and 2 cases of left hemicranial hypoplasia in semantic variant PPA.

Design/Methods DESIGN/METHODS: We screened the UCSF Memory and Aging Center's PPA cohort for hand preference and history of LD. The study included logopenic variant PPA (lvPPA), n=47; nonfluent variant PPA (nfvPPA), n=54; semantic variant (svPPA), n=96. An independent sample of svPPA, n=36, provided by Mayo Clinic Jacksonville and of PSP, n=107, obtained from UCSF were screened for solely for handedness.

Results RESULTS: There was nearly twice the prevalence of nRH in the svPPA cohort, half the prevalence of nRH in nfvPPA, and nRH consistent with handedness in the general population in lvPPA. These handedness findings were corroborated in our independent groups. In the lvPPA group there was a much greater likelihood of LD in comparison to the svPPA and nfvPPA groups. Within the lvPPA group patients with LD were younger and had increased global functioning at presentation than lvPPA without LD.

Conclusions CONCLUSIONS: A unique pattern of hand preference and history of language learning disability appears to correlate strongly with each subtype of PPA. This further strengthens previous findings in PPA and may provide new insights into how neurodevelopment affects neurodegenerative disease susceptibility.

Authors/Disclosures
Zachary Miller, MD (UCSF Memory and Aging Center) PRESENTER	Dr. Miller has nothing to disclose.
Christina R. Cook, PhD (DC2)	No disclosure on file
Katherine P. Rankin, PhD (University of California San Francisco)	The institution of Dr. Rankin has received research support from Marcus Foundation.
	No disclosure on file
Maya L. Henry, PhD	No disclosure on file
Stephen M. Wilson, PhD	No disclosure on file
	No disclosure on file
	No disclosure on file
Brianne Bettcher	No disclosure on file
David H. Margolin, MD, PhD (Genzyme Corporation)	Dr. Margolin has received personal compensation for serving as an employee of uniQure, Inc.. Dr. Margolin has stock in Cerevance, Inc. Dr. Margolin has stock in Datacubed Health. Dr. Margolin has stock in uniQure, Inc.. Dr. Margolin has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Howard J. Rosen, MD (UCSF)	Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly . Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities.
Joel Kramer, PhD (UCSF Medical Center)	The institution of Dr. Kramer has received research support from tau consortium. Dr. Kramer has received publishing royalties from a publication relating to health care.
Gil D. Rabinovici, MD, FAAN (UCSF Memory & Aging Center)	Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Norodisk. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for C2N. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Joihnson. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Peerview. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA. The institution of Dr. Rabinovici has received research support from NIH. The institution of Dr. Rabinovici has received research support from American College of Radiology. The institution of Dr. Rabinovici has received research support from Alzheimer's Association. The institution of Dr. Rabinovici has received research support from Rainwater Charitable Foundation. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Topic Chair, Course Director and teacher with AAN. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Invited speaker with ANA.
Neill R. Graff-Radford, MD, FAAN (Mayo Clinic Jacksonville)	The institution of Dr. Graff-Radford has received research support from Biogen. The institution of Dr. Graff-Radford has received research support from Lilly. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Biogen. Dr. Graff-Radford has received publishing royalties from a publication relating to health care.
William W. Seeley, MD	Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Council. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global Consulting. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BridgeBio. Dr. Seeley has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Seeley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lyterian Therapeutics. The institution of Dr. Seeley has received research support from NIH. The institution of Dr. Seeley has received research support from Rainwater Charitable Foundation. The institution of Dr. Seeley has received research support from Bluefield Project to Cure FTD. The institution of Dr. Seeley has received research support from Chan-Zuckerberg Initiative.
Bruce L. Miller, MD, FAAN (University of California, San Francisco)	Dr. Miller has nothing to disclose.
Maria Luisa Gorno Tempini, MD, PhD (UCSF Memory and Aging Center)	The institution of Dr. Gorno Tempini has received research support from the NIH.

��ɫ��

��ɫ��